Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Study of Docetaxel in Breast Cancer Patients
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 998
- Registration Number
- NCT00174707
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 97
- Registration Number
- NCT00160030
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT00135941
- Locations
- 🇺🇸
Advanced Healthcare, Milwaukee, Wisconsin, United States
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1088
- Registration Number
- NCT00134563
- Locations
- 🇨🇦
sanofi-aventis, Canada, Laval, Canada
🇸🇪Sanofi-Aventis, Bromma, Sweden
🇩🇪Sanofi-Aventis Deutschland GmbH, Berlin, Germany
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 281
- Registration Number
- NCT00135057
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 347
- Registration Number
- NCT00135083
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 345
- Registration Number
- NCT00135096
- Locations
- 🇺🇸
Sanofi-aventis, Bridgewater, New Jersey, United States
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-07-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 947
- Registration Number
- NCT00133731
- Locations
- 🇺🇸
Los Angeles Cardiology Associates, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00132925
- Locations
- 🇺🇸
Sanofi-Aventis, Inc., Bridgewater, New Jersey, United States
KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2009-08-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2051
- Registration Number
- NCT00132951
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Québec, Canada